On its earnings report today, Microsoft reported better-than-expected earnings and guidance, but issued first-quarter revenue guidance slightly below the Wall Street consensus. The poor revenue guidance was partly, but not completely, offset by slightly better-than expected guidance for first-quarter operating costs. Overall, the magnitude of the earnings beat was...
We have seen the test of the 20sma, being bought back with strong volume. Volume has been decreasing daily for the past 10 days. Today's sell-off is on the lowest volume yet (we are a couple hours away from the close though). Risk-reward-ratio makes sense placing a stop-loss below $252.
Microsoft announced today the release of a new dual-screen phone that runs the Android operating system (as opposed to the old Windows phones, which were limited in terms of what apps you could get). Since the announcement, the stock has bounced to a new support level and broken a downward trend line that it formed over the last few days. It's just recovered from...
SELL – GLAXOSMITHKLINE (GSK) GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. Fundamentals...